PerkinElmer to Acquire High-Throughput Screening Shop Evotec Tech for $30.5M | GenomeWeb
NEW YORK (GenomeWeb News) — PerkinElmer plans to acquire high-throughput screening Evotec Technologies for €23 million ($30.5 million) in cash, German parent company Evotec said late yesterday.
 
Evotec makes and sells tools for high-throughput and high-content cell and biochemical screening. PerkinElmer CEO Gregory Summe said in a statement that the acquisition will “help our customers speed target validations and lead optimization along the drug discovery value chain.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.